EUVIMEDEUVIMED entdecken
Crossref

Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug

Mingxing Huang, Weichen Wang, Yingwei Wang iD, Rang Wang, Lili Pan, Xin Li, Bo Li, Jingsong Zhang, Ruoxiang Wang, Yi Zhang, Rong Tian iD

Journal of Materials Chemistry B · 2025 · 13 (1) · 256-263

DOI: 10.1039/d4tb01798f ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Materials Chemistry B, 2025. Verfasst von Mingxing Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. rongtiannuclear@126.com. Hauptthemen laut MEDLINE: Carbocyanines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant tumors pose substantial treatment challenges due to their heterogeneity, metastatic potential, and therapeutic resistance, underscoring the urgent need for more effective treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbocyaninesHumansAnimalsMiceTissue DistributionAntineoplastic AgentsMice, NudeLutetiumRadioisotopesMice, Inbred BALB CRadiopharmaceuticalsCell ProliferationCell Line, TumorFemale

Substanzen

Carbocyaninesheptamethine cyanine dyeAntineoplastic AgentsLutetiumRadioisotopesRadiopharmaceuticalsLutetium-177

Autor:innen und Institutionen

  • Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. rongtiannuclear@126.com.
  • Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, China.
  • Nuclear Power Institute of China, National Engineering Research Center of Isotope and Medicine, and Radioisotope Engineering Technology Research Center of Sichuan, Chengdu, China.
  • Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
  • Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.

ORCID-Profile: Yingwei Wang, Rong Tian

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, M., Wang, W., Wang, Y., Wang, R., Pan, L., Li, X., Li, B., Zhang, J., Wang, R., Zhang, Y., & Tian, R. (2025). Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug. Journal of Materials Chemistry B, 13(1), 256-263. https://doi.org/10.1039/d4tb01798f

Vancouver

Huang M, Wang W, Wang Y, Wang R, Pan L, Li X, et al. Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug. Journal of Materials Chemistry B. 2025;13(1):256-263. doi:10.1039/d4tb01798f

BibTeX
@article{Huang2025,
  author = {Huang, Mingxing and Wang, Weichen and Wang, Yingwei and Wang, Rang and Pan, Lili and Li, Xin and Li, Bo and Zhang, Jingsong and Wang, Ruoxiang and Zhang, Yi and Tian, Rong},
  title = {Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug},
  journal = {Journal of Materials Chemistry B},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {256--263},
  doi = {10.1039/d4tb01798f}
}
Kostenlos starten →